Grégoire Boulouis1,2, Marc Antoine Labeyrie3,4, Jean Raymond5, Christine Rodriguez-Régent6,3, Anne Claire Lukaszewicz6,3, Damien Bresson3,4, Wagih Ben Hassen6,3, Denis Trystram6,3, Jean Francois Meder6,3, Catherine Oppenheim6,3, Olivier Naggara6,3. 1. INSERM U894, CH Sainte-Anne, Department of Neuroradiology, Université Paris-Descartes, 1 rue Cabanis, 75014, Paris, France. gregoireboulouis@gmail.com. 2. DHU NeuroVasc Paris Sorbonne, Paris, France. gregoireboulouis@gmail.com. 3. DHU NeuroVasc Paris Sorbonne, Paris, France. 4. Neuroradiology, and Neurosurgery, Université Paris Diderot Paris VII, Paris, France. 5. Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Notre-Dame Hospital, Montreal, Quebec, Canada. 6. INSERM U894, CH Sainte-Anne, Department of Neuroradiology, Université Paris-Descartes, 1 rue Cabanis, 75014, Paris, France.
Abstract
OBJECTIVES: To examine the clinical outcome of aneurysmal subarachnoid haemorrhage (aSAH) patients exposed to cerebral vasospasm (CVS)-targeted treatments in a meta-analysis and to evaluate the efficacy of intra-arterial (IA) approaches in patients with severe/refractory vasospasm. METHODS: Randomised controlled trials, prospective and retrospective observational studies reporting clinical outcomes of aSAH patients exposed to CVS targeted treatments, published between 2006-2016 were searched using PubMed, EMBASE and the Cochrane Library. The main endpoint was the proportion of unfavourable outcomes, defined as a modified Rankin score of 3-6 at last follow-up. RESULTS: Sixty-two studies, including 26 randomised controlled trials, were included (8,976 patients). At last follow-up 2,490 of the 8,976 patients had an unfavourable outcome, including death (random-effect weighted-average, 33.7%; 99% confidence interval [CI], 28.1-39.7%; Q value, 806.0; I 2 = 92.7%). The RR of unfavourable outcome was lower in patients treated with Cilostazol (RR = 0.46; 95% CI, 0.25-0.85; P = 0.001; Q value, 1.5; I 2 = 0); and in refractory CVS patients treated by IA intervention (RR = 0.68; 95% CI, 0.57-0.80; P < 0.0001; number needed to treat with IA intervention, 6.2; 95% CI, 4.3-11.2) when compared with the best available medical treatment. CONCLUSIONS: Endovascular treatment may improve the outcome of patients with severe-refractory vasospasm. Further studies are needed to confirm this result. KEY POINTS: • 33.7% of patients with cerebral Vasospasm following aneurysmal subarachnoid-hemorrhage have an unfavorable outcome. • Refractory vasospasm patients treated using endovascular interventions have lower relative risk of unfavourable outcome. • Subarachnoid haemorrhage patients with severe vasospasm may benefit from endovascular interventions. • The relative risk of unfavourable outcome is lower in patients treated with Cilostazol.
OBJECTIVES: To examine the clinical outcome of aneurysmal subarachnoid haemorrhage (aSAH) patients exposed to cerebral vasospasm (CVS)-targeted treatments in a meta-analysis and to evaluate the efficacy of intra-arterial (IA) approaches in patients with severe/refractory vasospasm. METHODS: Randomised controlled trials, prospective and retrospective observational studies reporting clinical outcomes of aSAHpatients exposed to CVS targeted treatments, published between 2006-2016 were searched using PubMed, EMBASE and the Cochrane Library. The main endpoint was the proportion of unfavourable outcomes, defined as a modified Rankin score of 3-6 at last follow-up. RESULTS: Sixty-two studies, including 26 randomised controlled trials, were included (8,976 patients). At last follow-up 2,490 of the 8,976 patients had an unfavourable outcome, including death (random-effect weighted-average, 33.7%; 99% confidence interval [CI], 28.1-39.7%; Q value, 806.0; I 2 = 92.7%). The RR of unfavourable outcome was lower in patients treated with Cilostazol (RR = 0.46; 95% CI, 0.25-0.85; P = 0.001; Q value, 1.5; I 2 = 0); and in refractory CVS patients treated by IA intervention (RR = 0.68; 95% CI, 0.57-0.80; P < 0.0001; number needed to treat with IA intervention, 6.2; 95% CI, 4.3-11.2) when compared with the best available medical treatment. CONCLUSIONS: Endovascular treatment may improve the outcome of patients with severe-refractory vasospasm. Further studies are needed to confirm this result. KEY POINTS: • 33.7% of patients with cerebral Vasospasm following aneurysmal subarachnoid-hemorrhage have an unfavorable outcome. • Refractory vasospasmpatients treated using endovascular interventions have lower relative risk of unfavourable outcome. • Subarachnoid haemorrhagepatients with severe vasospasm may benefit from endovascular interventions. • The relative risk of unfavourable outcome is lower in patients treated with Cilostazol.
Authors: P Jun; N U Ko; J D English; C F Dowd; V V Halbach; R T Higashida; M T Lawton; S W Hetts Journal: AJNR Am J Neuroradiol Date: 2010-07-08 Impact factor: 3.825
Authors: Martin Barth; Hans-Holger Capelle; Stephan Weidauer; Christel Weiss; Elke Münch; Claudius Thomé; Thomas Luecke; Peter Schmiedek; Hidetoshi Kasuya; Peter Vajkoczy Journal: Stroke Date: 2006-12-21 Impact factor: 7.914
Authors: Thomas Westermaier; Christian Stetter; Giles H Vince; Mirko Pham; Jose Perez Tejon; Jörg Eriskat; Ekkehard Kunze; Cordula Matthies; Ralf-Ingo Ernestus; Laszlo Solymosi; Klaus Roosen Journal: Crit Care Med Date: 2010-05 Impact factor: 7.598
Authors: Marike Zwienenberg-Lee; Jonathan Hartman; Nancy Rudisill; Lori Kennedy Madden; Karen Smith; Joseph Eskridge; David Newell; Bon Verweij; M Ross Bullock; Andrew Baker; William Coplin; Robert Mericle; Jian Dai; David Rocke; J Paul Muizelaar Journal: Stroke Date: 2008-04-17 Impact factor: 7.914
Authors: Sherry H-Y Chou; Eric E Smith; Neeraj Badjatia; Raul G Nogueira; John R Sims; Christopher S Ogilvy; Guy A Rordorf; Cenk Ayata Journal: Stroke Date: 2008-07-24 Impact factor: 7.914
Authors: M-A Labeyrie; S Gaugain; G Boulouis; A Zetchi; J Brami; J-P Saint-Maurice; V Civelli; S Froelich; E Houdart Journal: AJNR Am J Neuroradiol Date: 2019-07-18 Impact factor: 3.825
Authors: Martin Kieninger; Julia Flessa; Nicole Lindenberg; Sylvia Bele; Andreas Redel; André Schneiker; Gerhard Schuierer; Christina Wendl; Bernhard Graf; Vera Silbereisen Journal: Neurocrit Care Date: 2018-02 Impact factor: 3.210
Authors: Adnan I Qureshi; Ammad Ishfaq; Muhammad F Ishfaq; Abhi Pandhi; Sundas I Ahmed; Savdeep Singh; Ali Kerro; Rashi Krishnan; Aman Deep; Alexandros L Georgiadis Journal: J Vasc Interv Neurol Date: 2018-11
Authors: Martin Kieninger; Michael Gruber; Isabella Knott; Katja Dettmer; Peter J Oefner; Sylvia Bele; Christina Wendl; Simon Tuemmler; Bernhard Graf; Christoph Eissnert Journal: Neurocrit Care Date: 2019-08 Impact factor: 3.210
Authors: Chunyan Li; Timothy G White; Kevin A Shah; Wayne Chaung; Keren Powell; Ping Wang; Henry H Woo; Raj K Narayan Journal: Neurosurgery Date: 2021-05-13 Impact factor: 4.654